#AI Solutions #Singapore #Alzheimer's Disease #Neurophet

Neurophet Showcases AI Solutions for Alzheimer's at SEACURE Symposium

Neurophet, a pioneering firm in artificial intelligence for brain disorder diagnosis, made significant strides at the recent SEACURE symposium held on November 28, 2025, at Nanyang Technological University in Singapore. Led by co-CEOs Jake Junkil Been and Donghyeon Kim, the company demonstrated its commitment to advancing brain health through innovative technology.

The highlight of the event was Neurophet AQUA AD, a specialized software designed to monitor the effects of Alzheimer's disease treatments. By attending this symposium, Neurophet aimed to share its expertise and illustrate the clinical impacts of its solutions on healthcare practices across Southeast Asia. This initiative is designed to enhance the safety and effectiveness of treatments provided to patients with Alzheimer's disease.

During the symposium, Neurophet set up an exhibition booth where the team, including Chief Medical Officer Hyunkook Lim, presented their innovative AI-enabled brain imaging analysis solutions. Notably, Hyunkook Lim delivered a compelling talk titled, Neurophet: A Game-Changer in Clinical Practice, emphasizing real-world applications of their products in clinical settings throughout Korea. His presentation asserted the importance of the clinical value brought by Neurophet AQUA AD in managing treatment safety and monitoring for Alzheimer's patients.

Co-authoring the discussions was Professor Nagaendran Kandiah from the Lee Kong Chian School of Medicine at NTU. He presented findings related to the Validation of AI-based AQUA Software in the Southeast Asian BIOCIS Cohort, showcasing the software's clinical validity in identifying neurodegeneration in individuals suffering from mild cognitive impairments and dementia.

Jake Junkil Been underscored the benefits of highlighting Neurophet AQUA AD at the symposium, stating that the company hopes to expand its reach across Southeast Asian healthcare institutions, consequently reinforcing its role in improving patient care.

One of the remarkable aspects of the symposium was its vast participation, drawing approximately 220 neurologists from six Southeast Asian countries: Singapore, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. This gathering provided an excellent platform for sharing knowledge, research findings, and innovative strategies in combating common neurological disorders.

About Neurophet

Neurophet, founded in 2016, stands at the forefront of artificial intelligence development aimed at diagnosing support, creating treatment guides, and developing devices to assist in brain disorder management. Key products include:

• - Neurophet AQUA: A brain MRI analysis software designed to enhance the effectiveness of neuroimaging.
• - Neurophet SCALE PET: Software for quantitative analysis of PET images.
• - Neurophet tES/TMS LAB: Brain imaging treatment planning software for magnetic brain stimulation.
• - Neurophet AQUA AD: Software focused on tracking treatment efficacy and adverse effects specifically for Alzheimer's patients.
• - Neurophet AQUA MS: Software developed for the analysis of Multiple Sclerosis images.

With its focus on neural science, Neurophet aims to pioneer innovative solutions for brain diseases through the prowess of AI technology. The company's dedication to improving the lives of those impacted by neurological conditions remains its top priority.

As Neurophet continues on its path of exploration and innovation, it remains determined to make a significant contribution towards enhancing brain health solutions in the future.